Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
9 C0 S3 r1 o, ^. C Q5 }
' d3 P L C F3 D+ \; D
' w! `5 z4 A) Y% U8 `2 J# tSub-category:& ]; Y. M& l* }0 o1 W6 q% l* d# Q/ B- K
Molecular Targets 7 m* _5 k) o5 V
D/ J- X1 L1 t r! k5 ^
* p6 ~- f* I k! A, qCategory:& ]( C; \5 b( q; m) O
Tumor Biology i- W1 ~, E0 |3 f& }3 A P
; R9 q0 r. |' U9 _4 v! P3 n7 M, z0 c
6 @. G, [# ^- J0 @ RMeeting:
8 H9 g7 T' Z- s1 X2011 ASCO Annual Meeting / Q, P, E G6 B1 P- e
/ t) l' y, n) t3 F* _* [+ n) f5 k9 B) T2 `4 ~4 O3 J
Session Type and Session Title:3 J' l7 ~# w5 S) [) I
Poster Discussion Session, Tumor Biology
$ {5 g) |1 b8 O$ m$ y- @1 p8 @" R0 N
2 r+ o. w t- Q) t, ^% d; a
Abstract No:. _" q9 B% j( C8 |$ U2 {
10517 3 @8 ` S- ~4 i! @
/ \% \% a+ k# I6 n& { S: L
; `+ P& r+ l% @* U
Citation:
2 u; q# G" T2 O& c3 kJ Clin Oncol 29: 2011 (suppl; abstr 10517)
$ A) i# y' s( R3 O. j8 v
* s+ R7 Z, w! c% E# U- A; A4 r, ?) p+ i( e! N7 B5 s7 P: f
Author(s):
( X0 p7 x) |1 aJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China ! w; T! `- T# c
: O3 [) C. F: C+ F# R$ X
9 K: ^: M `" b& _7 F8 D; r; \! |
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.# N4 H8 e; j: D/ r5 F- h* E X( K! @' N
+ c* q2 E$ f/ \ ~& B1 [
Abstract Disclosures
8 Z, ^/ `1 f+ x3 }# a% q( j+ j, q& K
Abstract:5 h/ U% e& |+ _5 C4 D
* S& l4 ]$ _ S& `& j
3 r0 B6 S+ i. v: P+ sBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
7 u+ X; c0 \; d" C: i
. b+ ?/ P( L$ @- C" x% A
# l/ [5 o% n; c/ J |